查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球戊型肝炎诊断测试市场 - 2022-2029
市场调查报告书
商品编码
1129237

全球戊型肝炎诊断测试市场 - 2022-2029

Global Hepatitis E Diagnostic Tests Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

新型基于重组蛋白的戊型肝炎诊断试剂盒的开发有望推动市场增长。

Biotech Consortium India Limited 开发了一种高度敏感的检测技术，用于检测 HEV 感染，与其他市售检测试剂盒相比。该技术基于猪 HEV 的开放阅读框 2 开发戊型肝炎检测试剂盒。目前的技术已将基因序列改变了 2%，增加了 HEV 蛋白的产生，促进了患者血清样本中蛋白质的鑑定，并提高了诊断试剂盒的功效。这是一个可用于疫苗生产的技术平台。此外，该技术还具有检测基因型 1 和 4 的优势，灵敏度更高。因此，从上述陈述来看，预计将在预测期内推动市场。

约束

缺乏公众意识、诊断方法的高成本和不充分的报销规定是在预测期内阻碍市场发展的因素。

全球戊型肝炎诊断测试市场 - 行业分析

戊型肝炎诊断测试市场根据波特五力、报销方案、定价分析和供应炼等各种行业因素对市场进行了深入分析。

COVID-19 影响分析

COVID-19 大流行对医疗保健系统和市场产生了适度影响。 COVID-19 疫情扰乱了医疗保健系统，使提供基本临床护理、戊型肝炎病毒抗体检测和治疗变得更加困难。结果，在大流行时未被诊断出患有戊型肝炎病毒的人随后被发现患有更晚期的疾病，可能导致发病率和死亡率增加。此外，作为 COVID-19 大流行缓解措施的一部分，CDC 发布了关于推迟常规护理和推迟非必要任务的指南。有了这个建议，患者应避免不必要的面对面咨询，并通过远程医疗、患者门户、电话和电子邮件与他们的医疗保健提供者沟通。

此外，大流行还将扰乱供应炼和流程。许多公司将转移到其他地区以确保产品可用性并保护其供应链。因此，从上面这句话来看，市场受到了影响，预计随着经济活动的恢復，市场将迅速获得牵引力。

全球戊型肝炎诊断测试市场报告提供了大约 45 多个市场数据表、40 多个数字和 180 页。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因子
    • 驱动程序
      • 新型基于重组蛋白的戊型肝炎诊断试剂盒的开发有望推动市场增长。
    • 限制因素
      • 预计诊断方法的高成本和不完善的报销规定将阻碍市场增长。
    • 市场进入机会
    • 影响分析

第五章行业分析

  • 供应链分析
  • 定价分析
  • 未满足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按产品类型

  • ELISA HEV IgM 检测试剂盒
  • ELISA HEV IgG 检测试剂盒
  • RT-PCR检测试剂盒
  • 其他

第 8 章按测试类型

  • 血
  • 航班
  • 其他

第 9 章，最终用户

  • 医院
  • 诊断实验室
  • 护理点
  • 其他

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准
  • 值得关注的重点公司列表

第 12 章公司简介

  • 诊断自动化/Cortez Diagnostics, Inc.
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • EUROIMMUN Medizinische Labordiagnostika AG
  • Dia.Pro-Diagnostic Bioprobes s.r.l
  • Biokit S.A.
  • altona Diagnostics GmbH
  • ORGENTEC Diagnostika
  • Fortress Diagnostics
  • Mikrogen GmBH
  • Primerdesign Ltd
  • F. Hoffmann-La Roche Ltd.

第 13 章全球戊型肝炎诊断测试市场-DataM

简介目录
Product Code: DM5780

Market Overview

Hepatitis E Diagnostic Tests Market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 4.5 % during the forecast period (2022-2029).

The hepatitis E virus causes the enteric liver disease known as hepatitis E. (HEV). It belongs to the group of five known human hepatitis viruses (A, B, C, D, and E). Due to the feces in the water being a source of contamination, it is spread by fecal-oral contact. Hepatitis E cannot currently be diagnosed using an officially recognized test. Doctors rely on testing to identify the antibodies that fight the virus to diagnose hepatitis E correctly. It often relies on finding specific anti-HEV immunoglobulin M (IgM) antibodies to the virus in a person's blood; this is usually sufficient in regions where the disease is prevalent. For field use, rapid testing is available.

Market Dynamics

The development of a Novel Recombinant Protein-based Diagnostic Kit for Hepatitis E is expected to drive market growth.

Biotech Consortium India Limited has developed a technology that is a sensitive test for detecting HEV infection compared to other commercial assay kits. The technology is based on using Swine HEV's Open Reading Frame-2 for the development of Hepatitis E testing kits. The gene sequence underwent a 2-percent alteration in the current technology, leading to increased HEV protein production for better protein identification in the patient's sera sample and increased diagnostic kit effectiveness. This is a technology platform that can be used to create vaccines. Moreover, the technology benefits by detecting genotypes 1& 4 and has higher sensitivity. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

Lack of awareness among the population, high cost of diagnostic procedures and inadequate reimbursement regulations are some factors the market is expected to hamper in the forecast period.

Global Hepatitis E Diagnostic Tests Market - Industry Analysis

The hepatitis E diagnostic tests market provides in-depth analysis of the market based on various industry factors such as porter's five forces, reimbursement scenario, pricing analysis, supply chain etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. The COVID-19 pandemic has disrupted healthcare systems, making it more difficult to provide basic clinical care, hepatitis E virus antibody testing, and treatment. As a result, increased morbidity and mortality rates may result from those who had undiagnosed hepatitis E virus during the pandemic subsequently being found to have the disease in more advanced stages. Moreover, as part of the original COVID-19 pandemic mitigation initiatives, the CDC published guidelines on deferring routine clinical visits and delaying non-essential operations. By this advice, patients should avoid making unnecessary in-person visits and communicate with their healthcare practitioner via telemedicine, patient portals, phone, and email.

Additionally, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Segment Analysis

ELISA HEV IgM Test kits segment is expected to hold the largest market share in hepatitis E diagnostic tests market

The ELISA HEV IgM test kits segment is expected to dominate in 2021. HEV infection typically takes 2 to 6 weeks to develop. HEV RNA and anti-HEV IgM antibodies can be found at the time of diagnosis, followed by anti-HEV IgG antibodies. Positive anti-HEV IgM antibody results in serum can significantly indicate acute HEV infection. Anti-HEV IgM antibodies typically only remain positive for a few months (about 3-4 mo), although occasionally they do. The precise length of this response is still unknown. However, the anti-HEV IgG antibody is comparatively long-lasting.

Additionally, the avidity of the anti-HEV IgG antibody increases over time. Therefore, the demand for the ELISA HEV IgM Test kits increases. It is because it is a third-generation Enzyme ImmunoAssay (ELISA) for qualitatively determining IgG antibodies to Hepatitis E Virus in human plasma and sera. The kit is intended for the follow-up of HEV-infected patients. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

Asia Pacific region holds the largest market share in the global hepatitis E diagnostic tests market

In 2021, Asia Pacific accounted for the highest revenue share. The increasing prevalence of Hepatitis E cases, rising geriatric population, increasing consumption of pork, rise in adoption of Hepatitis E tests and product launches by the market players in the region are some factors the market is expected to boost in the forecast period. For instance, according to the National Center for Biotechnology Information, nearly 60% of blood donors in India have circulating anti-HEV IgG antibodies, indicating prior exposure to the virus, indicating that HEV infection and illness are extremely endemic country. The seroprevalence rates differ by age, with older people having greater rates. 5 Hepatitis E causes almost half of all instances of acute hepatitis and a comparable percentage of cases of acute liver failure (ALF).

Moreover, the middle and northern regions of India are where most of the country's pigs are found. Assam had more than two million people in 2019. Since swine is thought to be the main carrier of HEV, the largest pork intake suggests that the disease is spread through zoonotic agents. Thus, it has increased the demand for hepatitis E diagnostic tests, due to which the Asia Pacific is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the hepatitis E diagnostic tests market are Diagnostic Automation / Cortez Diagnostics, Inc., EUROIMMUN Medizinische Labordiagnostika AG, Dia.Pro - Diagnostic Bioprobes s.r.l , Biokit S.A., altona Diagnostics GmbH, ORGENTEC Diagnostika, Fortress Diagnostics, Mikrogen GmBH, Primerdesign Ltd, F. Hoffmann-La Roche Ltd.

altona Diagnostics GmbH:

Overview:

altona Diagnostics is a privately held medical diagnostic company headquartered in Hamburg-Altona, Germany. The business creates and produces in-vitro diagnostic tests for the DNA-based identification of pathogens like viruses, bacteria, and parasites. The company has over 20 years of experience in the molecular diagnostics industry and has received the ISO 13485 certification. Through subsidiaries and more than 40 distribution partners, altona Diagnostics provides its certified products to private and clinical laboratories worldwide. Additionally, altona Diagnostics' diagnostic tests are offered as ready-to-use kits based on real-time PCR technology. Over 50 CE-marked kits compatible with open real-time PCR platforms are available in the company's product line. Further, altona Diagnostics provides an automated workflow system that includes apparatus, specialized software, and chemistry for nucleic acid extraction.

Product Portfolio:

RealStar HEV RT-PCR Kit 2.0: The RealStar HEV RT-PCR Kit 2.0 is an in vitro diagnostic test, based on real-time PCR technology, for detecting and quantifying hepatitis E virus (HEV) specific RNA.

The global hepatitis E diagnostic tests market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The development of a Novel Recombinant Protein-based Diagnostic Kit for Hepatitis E is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of diagnostic procedures and inadequate reimbursement regulations are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type Segment
  • 7.2. ELISA HEV IgM Test kits*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. ELISA HEV IgG Test Kits
  • 7.4. RT-PCR Test Kits
  • 7.5. Others

8. By Test Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 8.1.2. Market Attractiveness Index, By Test Type Segment
  • 8.2. Blood*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Stool
  • 8.4. Others

9. By End user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.1.2. Market Attractiveness Index, By End user Segment
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Diagnostic Laboratories
  • 9.4. Point of Care
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Diagnostic Automation / Cortez Diagnostics, Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. EUROIMMUN Medizinische Labordiagnostika AG
  • 12.3. Dia.Pro - Diagnostic Bioprobes s.r.l
  • 12.4. Biokit S.A.
  • 12.5. altona Diagnostics GmbH
  • 12.6. ORGENTEC Diagnostika
  • 12.7. Fortress Diagnostics
  • 12.8. Mikrogen GmBH
  • 12.9. Primerdesign Ltd
  • 12.10. F. Hoffmann-La Roche Ltd.

LIST NOT EXHAUSTIVE

13. Global Hepatitis E Diagnostic Tests Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Applications
  • 13.3. Contact Us